Aurora Cannabis Inc. (ACB) is gaining momentum in the improving cannabis stock market amid a gradual regulatory shift. Notably, after years of restructuring, ACB’s focus has shifted to high-margin international medical cannabis, particularly in Europe, where it has significant market presence in countries like Germany, Poland, Australia, and New Zealand.
In the latest fiscal quarter, ACB reported a 17% year-over-year increase in international medical cannabis revenue, while overall revenue declined due to winding down consumer operations. The company has no debt and finished June with approximately C$149 million in cash. Analysts have also raised earnings expectations for ACB, marking a shift from projected losses to anticipated profits within 60 days.
Despite risks, such as a challenging Canadian market and ongoing regulatory complexity, Aurora’s stock is experiencing positive technical trends, pushing it closer to year-to-date highs. The company has also exceeded earnings estimates in its last four quarters, last reporting adjusted earnings of $0.04 per share against expectations of a loss.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
